Intra-Cellular Therapies - ITCI Stock Forecast, Price & News

11 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Intra-Cellular Therapies in the last twelve months. There are currently 2 hold ratings and 9 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ITCI shares.
View ITCI analyst ratings or view top-rated stocks.

11 brokerages have issued 12 month price objectives for Intra-Cellular Therapies' stock. Their ITCI share price forecasts range from $49.00 to $98.00. On average, they predict the company's stock price to reach $71.92 in the next twelve months. This suggests a possible upside of 32.8% from the stock's current price.
View analysts price targets for ITCI or view top-rated stocks among Wall Street analysts.

Intra-Cellular Therapies' stock was trading at $52.92 on January 1st, 2023. Since then, ITCI shares have increased by 2.3% and is now trading at $54.15.
View the best growth stocks for 2023 here.

Intra-Cellular Therapies saw a decrease in short interest in the month of March. As of March 15th, there was short interest totaling 2,610,000 shares, a decrease of 21.1% from the February 28th total of 3,310,000 shares. Based on an average trading volume of 672,700 shares, the days-to-cover ratio is presently 3.9 days.
View Intra-Cellular Therapies' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 9th 2023.
View our ITCI earnings forecast.

Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) released its quarterly earnings results on Wednesday, March, 1st. The biopharmaceutical company reported ($0.45) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.62) by $0.17. The biopharmaceutical company had revenue of $87.87 million for the quarter, compared to the consensus estimate of $86.97 million. Intra-Cellular Therapies had a negative trailing twelve-month return on equity of 35.88% and a negative net margin of 102.37%. Intra-Cellular Therapies's revenue for the quarter was up 242.3% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($1.05) EPS.

ETFs with the largest weight of Intra-Cellular Therapies (NASDAQ:ITCI) stock in their portfolio include Psyk Etf (PSYK), AdvisorShares Psychedelics ETF (PSIL), iShares Neuroscience and Healthcare ETF (IBRN), SPDR S&P Pharmaceuticals ETF (XPH), Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL), iShares U.S. Pharmaceuticals ETF (IHE), Virtus LifeSci Biotech Products ETF (BBP) and Principal Healthcare Innovators ETF (BTEC).

Based on aggregate information from My MarketBeat watchlists, some companies that other Intra-Cellular Therapies investors own include Sorrento Therapeutics (SRNE), Amarin (AMRN), Gilead Sciences (GILD), CRISPR Therapeutics (CRSP), Synergy Pharmaceuticals (SGYP), Myovant Sciences (MYOV), Novavax (NVAX), Pfizer (PFE), AbbVie (ABBV) and Clovis Oncology (CLVS).

Intra-Cellular Therapies trades on the NASDAQ under the ticker symbol "ITCI."

Intra-Cellular Therapies' stock is owned by a number of institutional and retail investors. Top institutional investors include Alliancebernstein L.P. (2.13%), Franklin Resources Inc. (1.89%), Geode Capital Management LLC (1.76%), JPMorgan Chase & Co. (1.58%), GW&K Investment Management LLC (1.53%) and Millennium Management LLC (1.47%). Insiders that own company stock include Christopher D Alafi, Christopher D Alafi, Joel S Marcus, Lawrence J Hineline, Lawrence J Hineline, Mark Neumann, Michael Halstead, Nostrand Robert L Van, Rory B Riggs, Sharon Mates and Suresh K Durgam.
View institutional ownership trends.

Shares of ITCI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ITCI stock can currently be purchased for approximately $54.15.

Intra-Cellular Therapies (NASDAQ:ITCI) has a market capitalization of $5.16 billion and generates $250.31 million in revenue each year. The biopharmaceutical company earns $-256,260,000.00 in net income (profit) each year or ($2.72) on an earnings per share basis.

The company employs 512 workers across the globe.

Intra-Cellular Therapies' mailing address is 430 EAST 29TH STREET, NEW YORK NY, 10016. The official website for the company is www.intracellulartherapies.com. The biopharmaceutical company can be reached via phone at (464) 440-9333, via email at ir@intracellulartherapies.com, or via fax at 646-440-9334.